Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch

Pearson, Frances E., Muller, David A., Roalfe, Lucy, Zancolli, Marta, Goldblatt, David and Kendall, Mark A.F. (2015) Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch. Vaccine, 33 48: 6675-6683. doi:10.1016/j.vaccine.2015.10.081


Author Pearson, Frances E.
Muller, David A.
Roalfe, Lucy
Zancolli, Marta
Goldblatt, David
Kendall, Mark A.F.
Title Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch
Journal name Vaccine   Check publisher's open access policy
ISSN 1873-2518
0264-410X
Publication date 2015-11-27
Year available 2015
Sub-type Article (original research)
DOI 10.1016/j.vaccine.2015.10.081
Open Access Status Not yet assessed
Volume 33
Issue 48
Start page 6675
End page 6683
Total pages 9
Place of publication London, United Kingdom
Publisher Elsevier
Language eng
Abstract Adequate access to effective and affordable vaccines is essential for the prevention of mortality due to infectious disease. Pneumonia – a consequence of Streptococcus pneumoniae infection – is the world's leading cause of death in children aged under 5 years. The development of a needle-free, thermostable pneumococcal-conjugate vaccine (PCV) could revolutionise the field by reducing cold-chain and delivery constraints. Skin patches have been used to deliver a range of vaccines, with some inducing significantly higher vaccine-specific immunogenicity than needle-injected controls in pre-clinical models, though they have yet to be used to deliver a PCV. We dry-coated a licensed PCV onto a microprojection-based patch (the Nanopatch) and delivered it to mouse skin. We analysed resulting anti-polysaccharide IgG responses. With and without adjuvant, anti-polysaccharide IgG titres induced by Nanopatch immunisation were significantly higher than dose-matched intramuscular controls. These improved responses were primarily obtained against pneumococcal serotypes 4 and 14. Importantly, capsule-specific IgG correlated with functionality in an opsonophagocytic killing assay. We demonstrate enhanced anti-PCV immunogenicity when delivered by Nanopatch over intramuscular injection. As the first study of a PCV delivered by a skin vaccination technology, this report indicates the potential for reduced costs and greater global distribution of such a vaccine.
Keyword Skin vaccination
Polysaccharide
Pneumococcal-conjugate vaccine
Vaccine delivery
Microprojection
Opsonophagocytic killing assay
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 3 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 29 Dec 2015, 11:40:27 EST by System User on behalf of Scholarly Communication and Digitisation Service